Trial Profile
A Phase 1 Study of LY3127804 as Monotherapy and in Combination With Ramucirumab in Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Oct 2020
Price :
$35
*
At a glance
- Drugs Ramucirumab (Primary) ; Zansecimab (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Carcinoma; Cervical cancer; Endometrial cancer; Gastric cancer; Oesophageal cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man
- Acronyms JQBA
- Sponsors Eli Lilly and Company
- 16 Oct 2020 Status changed from active, no longer recruiting to completed.
- 03 Aug 2020 Results (n=62) determining the RP2D and schedule of LY3127804 as monotherapy and combination with ramucirumabpublished in the British Journal of Cancer
- 04 May 2020 Planned End Date changed from 22 May 2020 to 20 Nov 2020.